GlassScriptPhysician profile
Carrie Collin
NPI 1194230961
$3,413.66
in general payments reported to CMS, 2019-2025
31 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $1,064 · 2023: $453 · 2024: $866 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $431.47 | 2022-2024 | Erleada |
| Sumitomo Pharma America, INC. | $346.48 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $324.52 | 2021-2025 | Veozah, Myrbetriq |
| Antares Pharma, INC. | $274.53 | 2021-2025 | Xyosted |
| Axonics, INC. | $272.77 | 2021-2022 | |
| Pfizer INC. | $223.31 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.99 | 2023-2025 | |
| Myovant Sciences INC. | $173.46 | 2021-2022 | |
| Teleflex LLC | $147.70 | 2021 | |
| Endo Pharmaceuticals INC. | $109.15 | 2021-2024 | Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $107.02 | 2021-2024 | Lynparza |
| Urovant Sciences INC | $100.05 | 2021-2022 | |
| Abbvie INC. | $89.51 | 2024 | |
| Endo USA, INC. | $71.50 | 2024 | Xiaflex, Aveed |
| Boston Scientific Corporation | $58.47 | 2024 | Ams 800 Artificial Urinary Sphincter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $54.76 | 2023-2024 | |
| Tempus Ai, INC | $53.96 | 2024 | |
| Merck Sharp & Dohme LLC | $53.93 | 2021-2022 | |
| Angiodynamics, INC. | $46.89 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $46.54 | 2022-2023 | Seglentis |
| Verity Pharmaceuticals INC. | $33.79 | 2025 | Tlando |
| Urogen Pharma, INC. | $28.72 | 2025 | |
| Dendreon Pharmaceuticals LLC | $26.55 | 2025 | Provenge |
| Pacira Pharmaceuticals Incorporated | $23.46 | 2024 | Iovera, Exparel |
| Laborie Medical Technologies Corp. | $18.20 | 2025 | |
| Accord Healthcare, INC. | $16.48 | 2025 | |
| Medtronic, INC. | $16.22 | 2024 | Interstim |
| Olympus America INC. | $16.11 | 2025 | Itind System |
| Coloplast Corp | $15.11 | 2025 | |
| Acerus Pharmaceuticals Corporation | $14.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Collin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.